BioRelix Pharmaceuticals

BioRelix, Inc. is a drug discovery and development company focused on identifying new anti-infective therapeutic agents. BioRelix is building a portfolio of anti-infective product candidates based on novel patented RNA targets, known as Riboswitches, identified by Ronald Breaker, Ph.D., Howard Hughes Investigator and Henry Ford II Professor, in his laboratory at Yale University.